Moreover, many combination therapies that include such immune checkpoint inhibitors, chemo- or radiation therapy, and another immunotherapy agent (such as an indoleamine 2,3-dioxygenase-1 [IDO1] inhibitor), have been explored to treat various solid tumors, including advanced-stage NSCLC [7–14]. Here, IDO1 is linked to non-small cell lung carcinoma.